文献速递MDS 与骨髓增殖性肿瘤血栓与止血

二甲双胍对老年真性红细胞增多症或原发性血小板增多症合并糖尿病患者血栓发生率的影响

Impact of Metformin on the Incidence of Thrombosis in Older Adults with Polycythemia Vera or Essential Thrombocythemia and Diabetes.
PubMed 文献 · Blood Adv · 2026-10-06

本研究基于SEER-Medicare数据库回顾性分析1153例≥66岁PV或ET合并糖尿病患者,评估二甲双胍使用与血栓风险的关联。结果显示二甲双胍使用与血栓风险降低独立相关(HR=0.78),尤其在重度糖尿病(HR=0.58)及无既往血栓患者中,且获益主要见于动脉血栓。

要点

  • 二甲双胍使用与PV/ET合并糖尿病患者血栓风险降低独立相关(HR=0.78)。
  • 重度糖尿病患者获益更显著(HR=0.58),轻度糖尿病无显著关联。
  • 获益主要针对动脉血栓,静脉血栓未显示显著关联。

核心结论

  • 二甲双胍使用与老年PV/ET合并糖尿病患者较低的血栓风险相关,尤其在重度糖尿病患者中。

研究设计与样本

  • 回顾性研究,使用SEER-Medicare关联数据库,纳入2008-2019年诊断的≥66岁PV或ET合并糖尿病患者1153例(PV 528例,ET 629例)。

主要发现

  • 二甲双胍使用与整体血栓风险降低独立相关(HR=0.78,95%CI 0.64-0.95,p=0.02)。
  • 重度糖尿病患者中关联更显著(HR=0.58,95%CI 0.38-0.89,p=0.01),轻度糖尿病无显著关联(HR=0.87,95%CI 0.68-1.11,p=0.27)。
  • 无既往血栓患者中关联显著(HR=0.78,95%CI 0.62-0.97,p=0.02)。
  • 获益主要见于动脉血栓,静脉血栓未显示显著关联。

临床怎么用

  • 对于PV/ET合并重度糖尿病的老年患者,二甲双胍的使用可能与较低血栓风险相关,可考虑作为降糖治疗的选择之一。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Individuals with myeloproliferative neoplasms (MPNs) have an increased thrombotic risk, particularly in the presence of cardiovascular comorbidities such as diabetes (DM). Metformin (MET) has been associated with a reduced incidence of MPNs; however, data on its association with thrombotic outcomes in polycythemia vera (PV) and essential thrombocythemia (ET) are limited. We conducted a retrospective study using the Surveillance, Epidemiology, and End Results-Medicare-linked database to evaluate the association between MET use and thrombotic risk in patients with MPNs and DM. We included patients with DM aged ≥66 years diagnosed with PV or ET between 2008-2019, continuously enrolled in Medicare Parts A/B/D, and followed for ≥6 months after diagnosis. Adjusted competing risk models were used to evaluate the association between MET and thrombotic risk. Among 1153 eligible patients (PV, n=528; ET, n=629), 846 (73.4%) had mild and 307 (26.6%) had severe DM. A total of 431 (37.4%) used MET. Overall, 485 (42.1%) patients experienced thrombosis after MPN diagnosis. MET use was independently associated with a reduced thrombotic risk (hazard ratio [HR]=0.78, 95% confidence interval [CI]: 0.64-0.95; p=0.02), especially among patients with severe DM (HR=0.58, 95% CI: 0.38-0.89; p=0.01), and those without prior thrombosis (HR=0.78, 95% CI: 0.62-0.97; p=0.02), but not among those with mild DM (HR=0.87, 95% CI: 0.68-1.11; p=0.27). When evaluating thrombotic event types separately, this benefit applied to arterial, but not venous thrombosis. MET use was associated with a lower thrombotic risk in older patients with PV/ET, primarily in individuals with severe DM.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Stempel JM, Wang R, Shallis RM, et al. Impact of Metformin on the Incidence of Thrombosis in Older Adults with Polycythemia Vera or Essential Thrombocythemia and Diabetes. Blood Adv. 2026. PMID: 42837664. doi:10.1182/bloodadvances.2026020767

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。